{"data":{"disease":"type-1-diabetes","question":"What combination of interventions could produce safe, durable functional remission or insulin independence in established Type 1 Diabetes?","population":{"t1dTrials":2836,"cureDirected":325,"managementAndOther":2511,"definition":"Trials whose listed conditions name Type 1 Diabetes."},"tracks":[{"id":"A","name":"Autoimmune tolerance","question":"Can the autoimmune attack on beta cells be selectively stopped or retrained?","topics":["antigen-specific tolerance","regulatory T-cell therapy","T-cell and B-cell targeting","checkpoint pathways","autoantigens (insulin, GAD65, IA-2, ZnT8)"],"trials":109,"open":24,"completed":60,"withPostedResults":36,"byStage":{"at-risk":12,"new-onset":39,"unspecified":47,"prevention":6,"established":5},"byPhase":{"PHASE3":11,"PHASE2":46,"PHASE1":15,"not stated":14,"PHASE4":2,"PHASE1/PHASE2":17,"EARLY_PHASE1":3,"PHASE2/PHASE3":1},"samples":[{"nctId":"NCT07222137","title":"A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults","status":"recruiting","phase":["PHASE3"],"stage":"at-risk","url":"https://negativeresistance.com/api/v1/trials/NCT07222137"},{"nctId":"NCT07222332","title":"A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)","status":"recruiting","phase":["PHASE3"],"stage":"new-onset","url":"https://negativeresistance.com/api/v1/trials/NCT07222332"},{"nctId":"NCT07142252","title":"Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus","status":"recruiting","phase":["PHASE2"],"stage":"new-onset","url":"https://negativeresistance.com/api/v1/trials/NCT07142252"},{"nctId":"NCT03929601","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"active","phase":["PHASE2"],"stage":"new-onset","url":"https://negativeresistance.com/api/v1/trials/NCT03929601"},{"nctId":"NCT06688331","title":"Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody","status":"recruiting","phase":["PHASE2"],"stage":"at-risk","url":"https://negativeresistance.com/api/v1/trials/NCT06688331"}]},{"id":"B","name":"Beta-cell restoration","question":"Can insulin-producing cells be preserved, restored or replaced?","topics":["stem-cell-derived islets","islet transplantation","pancreas transplantation","endogenous regeneration","beta-cell preservation agents","reprogramming and transdifferentiation"],"trials":149,"open":26,"completed":73,"withPostedResults":20,"byStage":{"unspecified":126,"established":6,"new-onset":15,"at-risk":1,"prevention":1},"byPhase":{"PHASE1":24,"PHASE1/PHASE2":33,"PHASE2/PHASE3":2,"PHASE3":10,"not stated":37,"PHASE2":40,"EARLY_PHASE1":2,"PHASE4":1},"samples":[{"nctId":"NCT06305286","title":"Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)","status":"active","phase":["PHASE1","PHASE2"],"stage":"established","url":"https://negativeresistance.com/api/v1/trials/NCT06305286"},{"nctId":"NCT05791201","title":"A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes","status":"active","phase":["PHASE1","PHASE2"],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/NCT05791201"},{"nctId":"NCT07804849","title":"Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes","status":"recruiting","phase":["PHASE2","PHASE3"],"stage":"new-onset","url":"https://negativeresistance.com/api/v1/trials/NCT07804849"},{"nctId":"NCT07061574","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"recruiting","phase":["PHASE1","PHASE2"],"stage":"new-onset","url":"https://negativeresistance.com/api/v1/trials/NCT07061574"},{"nctId":"NCT04786262","title":"A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes","status":"recruiting","phase":["PHASE3"],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/NCT04786262"}]},{"id":"C","name":"Graft survival and protection","question":"Can new insulin-producing cells be kept alive and protected without lifelong broad immunosuppression?","topics":["immune-evasive cell engineering","encapsulation devices","localized immune modulation","graft vascularization and oxygenation","transplant immunosuppression regimens"],"trials":38,"open":8,"completed":24,"withPostedResults":8,"byStage":{"established":2,"new-onset":3,"unspecified":32,"prevention":1},"byPhase":{"PHASE1/PHASE2":11,"PHASE2":17,"not stated":6,"PHASE1":3,"PHASE3":1},"samples":[{"nctId":"NCT06305286","title":"Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)","status":"active","phase":["PHASE1","PHASE2"],"stage":"established","url":"https://negativeresistance.com/api/v1/trials/NCT06305286"},{"nctId":"NCT06111586","title":"Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)","status":"active","phase":["PHASE2"],"stage":"new-onset","url":"https://negativeresistance.com/api/v1/trials/NCT06111586"},{"nctId":"NCT02064309","title":"An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus","status":"active","phase":["PHASE1","PHASE2"],"stage":"established","url":"https://negativeresistance.com/api/v1/trials/NCT02064309"},{"nctId":"ISRCTN85031369","title":"Balancing \"bad\" and \"good\" immune cells: testing a novel method for monitoring an immunosuppression strategy in people with Type 1 diabetes","status":"active","phase":[],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/ISRCTN85031369"},{"nctId":"NCT07470593","title":"Study of Glucose Tolerance Abnormalities Using Continuous Glucose Monitoring for the Identification of Early Loss of Pancreatic Islet Graft Function.","status":"recruiting","phase":[],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/NCT07470593"}]},{"id":"D","name":"Combination therapies","question":"Do complementary interventions together reach what each alone cannot?","topics":["tolerance plus beta-cell replacement","tolerance plus graft protection","multi-agent immune regimens"],"trials":13,"open":3,"completed":8,"withPostedResults":1,"byStage":{"at-risk":1,"new-onset":2,"unspecified":10},"byPhase":{"PHASE2":6,"not stated":1,"PHASE1":1,"PHASE1/PHASE2":4,"PHASE3":1},"samples":[{"nctId":"NCT06688331","title":"Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody","status":"recruiting","phase":["PHASE2"],"stage":"at-risk","url":"https://negativeresistance.com/api/v1/trials/NCT06688331"},{"nctId":"NCT06111586","title":"Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)","status":"active","phase":["PHASE2"],"stage":"new-onset","url":"https://negativeresistance.com/api/v1/trials/NCT06111586"},{"nctId":"ISRCTN85031369","title":"Balancing \"bad\" and \"good\" immune cells: testing a novel method for monitoring an immunosuppression strategy in people with Type 1 diabetes","status":"active","phase":[],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/ISRCTN85031369"},{"nctId":"NCT03444064","title":"PolyTreg Immunotherapy in Islet Transplantation","status":"completed","phase":["PHASE1"],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/NCT03444064"},{"nctId":"NCT03182426","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"completed","phase":["PHASE1","PHASE2"],"stage":"new-onset","url":"https://negativeresistance.com/api/v1/trials/NCT03182426"}]},{"id":"E","name":"Genetic and immunogenetic mechanisms","question":"Which genetic and immune-recognition mechanisms drive onset and persistence, as association versus demonstrated cause?","topics":["HLA susceptibility","T-cell receptor specificity","autoantibody screening and natural history","non-HLA genetic risk","beta-cell vulnerability"],"trials":70,"open":27,"completed":25,"withPostedResults":5,"byStage":{"established":1,"unspecified":52,"new-onset":3,"at-risk":8,"prevention":6},"byPhase":{"PHASE1/PHASE2":2,"not stated":55,"PHASE3":4,"PHASE2":5,"PHASE1":2,"PHASE4":2},"samples":[{"nctId":"NCT07831798","title":"VV-14300 for the Treatment of Type 1 Diabetes","status":"not_yet_recruiting","phase":["PHASE1","PHASE2"],"stage":"established","url":"https://negativeresistance.com/api/v1/trials/NCT07831798"},{"nctId":"NCT07490964","title":"Polycystic Ovary Syndrome in Type 1 Diabetes","status":"recruiting","phase":[],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/NCT07490964"},{"nctId":"NCT06984185","title":"Early Detection of Type 1 Diabetes","status":"recruiting","phase":[],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/NCT06984185"},{"nctId":"NCT07038473","title":"Early Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF)","status":"recruiting","phase":[],"stage":"at-risk","url":"https://negativeresistance.com/api/v1/trials/NCT07038473"},{"nctId":"NCT06908057","title":"Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)","status":"active","phase":[],"stage":"unspecified","url":"https://negativeresistance.com/api/v1/trials/NCT06908057"}]}],"stages":{"unspecified":2552,"established":47,"at-risk":28,"new-onset":127,"prevention":82},"outcomeLadder":[{"id":"disease-management","category":"Disease management","meaning":"Improved glucose control while continuing insulin therapy.","trialsMeasuring":1813,"ledgerClaims":1},{"id":"disease-modification","category":"Disease modification","meaning":"Measurable alteration of underlying disease biology.","trialsMeasuring":149,"ledgerClaims":5},{"id":"beta-cell-preservation","category":"Beta-cell preservation","meaning":"Retention of measurable endogenous insulin production.","trialsMeasuring":291,"ledgerClaims":10},{"id":"partial-remission","category":"Partial functional remission","meaning":"Reduced insulin dependence with evidence of endogenous insulin production.","trialsMeasuring":363,"ledgerClaims":0},{"id":"insulin-independence","category":"Insulin independence","meaning":"No exogenous insulin over a clearly documented follow-up interval.","trialsMeasuring":48,"ledgerClaims":3},{"id":"durable-functional-cure-candidate","category":"Durable functional cure candidate","meaning":"Sustained insulin independence with adequate glycemic control, acceptable safety and sufficient follow-up.","trialsMeasuring":null,"ledgerClaims":0},{"id":"immune-tolerant-functional-cure-candidate","category":"Immune-tolerant functional cure candidate","meaning":"Durable insulin independence without ongoing systemic immunosuppression.","trialsMeasuring":null,"ledgerClaims":1},{"id":"biological-cure","category":"Biological cure","meaning":"Restoration of normal physiology with sustained resolution of the disease mechanism. Requires especially rigorous evidence.","trialsMeasuring":null,"ledgerClaims":0}],"ledger":{"claims":21,"sourceVerified":21,"contradicting":5,"agents":1,"cohorts":20,"hypotheses":0,"byClass":{"E1":20,"E2":1,"E3":0,"E4":0,"E5":0}},"method":"Population: every trial in the index whose listed conditions name Type 1 Diabetes. Tracks are assigned by published keyword patterns over each trial's title, summary, interventions and sponsor text; a trial can sit in several tracks, and D (combination) means it matched A together with B or C. Stage is the first matching stage pattern, else \"unspecified\". Outcome rungs count trials that registered an outcome measuring a proxy for that rung: measuring is not achieving. Counts only.","computedAt":"2026-10-19T05:17:51.161Z","page":"https://negativeresistance.com/cure/lab"},"_meta":{"schemaVersion":"1","correlationId":"req_EtbW49o8kPkA","timestamp":"2026-10-19T05:17:51.168Z","links":{"discovery":"https://negativeresistance.com/api/v1","openapi":"https://negativeresistance.com/api/v1/openapi.json","mcp":"https://negativeresistance.com/api/v1/mcp","agentCard":"https://negativeresistance.com/.well-known/agent.json","aiPlugin":"https://negativeresistance.com/.well-known/ai-plugin.json","sdk":"https://negativeresistance.com/api/v1/sdk","status":"https://negativeresistance.com/api/v1/status","provenance":"https://negativeresistance.com/api/v1/sources","contract":"https://negativeresistance.com/api/v1/contract","curriculum":"https://negativeresistance.com/api/v1/curriculum","graph":"https://negativeresistance.com/api/v1/graph","openQuestions":"https://negativeresistance.com/api/v1/open-questions","scoreboard":"https://negativeresistance.com/api/v1/scoreboard","findings":"https://negativeresistance.com/api/v1/findings","claims":"https://negativeresistance.com/api/v1/claims","threads":"https://negativeresistance.com/api/v1/threads","assignment":"https://negativeresistance.com/api/v1/assignment","changes":"https://negativeresistance.com/api/v1/changes","hello":"https://negativeresistance.com/api/v1/hello","errors":"https://negativeresistance.com/api/v1/errors","webhooks":"https://negativeresistance.com/api/v1/webhooks","a2a":"https://negativeresistance.com/api/v1/a2a","deadEnds":"https://negativeresistance.com/api/v1/dead-ends","decompositions":"https://negativeresistance.com/api/v1/decompositions","rungs":"https://negativeresistance.com/api/v1/rungs","methods":"https://negativeresistance.com/api/v1/methods","reality":"https://negativeresistance.com/api/v1/reality","council":"https://negativeresistance.com/api/v1/council","calibration":"https://negativeresistance.com/api/v1/calibration","freshness":"https://negativeresistance.com/api/v1/freshness","twin":"https://negativeresistance.com/api/v1/twin","twinExperiment":"https://negativeresistance.com/api/v1/twin/experiment","agentCardCanonical":"https://negativeresistance.com/.well-known/agent-card.json","collaborate":"https://negativeresistance.com/collaborate","manifesto":"https://negativeresistance.com/about","documentation":"https://negativeresistance.com/embed","connect":"https://negativeresistance.com/connect"}}}